Aridis Pharmaceuticals Inc.
| NASDAQ: ARDS |
| Healthcare / Biotechnology / USA |
| 1.23 | -0.0200 | -1.60% | Vol 43.01K | 1Y Perf -82.76% |
| Jun 27th, 2022 15:59 DELAYED |
| BID | 1.20 | ASK | 1.61 | ||
| Open | 1.30 | Previous Close | 1.25 | ||
| Pre-Market | - | After-Market | 1.37 | ||
| - - | 0.14 11.38% |
| Target Price | 9.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 686.18 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 5.12 | Earnings Rating | Neutral | |
| Market Cap | 21.77M | Earnings Date | 11th Aug 2022 | |
| Alpha | -0.04 | Standard Deviation | 0.19 | |
| Beta | 0.42 |
Today's Price Range 1.211.37 | 52W Range 0.88007.72 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -11.35% | ||
| 1 Month | 27.55% | ||
| 3 Months | -24.24% | ||
| 6 Months | -52.65% | ||
| 1 Year | -82.76% | ||
| 3 Years | -88.74% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 139.26 | |||
ROE last 12 Months | 319.08 | |||
ROA (5Y Avg) | -95.04 | |||
ROA last 12 Months | -223.31 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -770.63 | |||
Return on invested Capital Q | -1 042.89 | |||
Return on invested Capital Y | -198.20 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 15.71 | ||||
| 13.09 | ||||
| - | ||||
| -0.90 | ||||
| -2.05 | ||||
| -1.22 | ||||
| -1.15 | ||||
| 25.47M | ||||
| Forward PE | -2.64 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.40 | ||||
| 0.60 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | -1.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -3 535.10 | ||||
| -3 503.00 | ||||
| -2 324.00 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -63.67 | ||||
| -2.54 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.51 | -0.44 | 13.73 |
| Q04 2021 | -0.58 | -0.92 | -58.62 |
| Q03 2021 | -0.54 | -1.94 | -259.26 |
| Q02 2021 | -0.57 | -0.55 | 3.51 |
| Q01 2021 | -0.60 | -0.77 | -28.33 |
| Q04 2020 | -0.54 | -0.59 | -9.26 |
| Q03 2020 | -0.55 | -0.65 | -18.18 |
| Q02 2020 | -0.72 | -0.47 | 34.72 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.06 | 40.00 | Positive |
| 9/2022 QR | -0.08 | - | - |
| 12/2022 FY | -0.34 | - | - |
| 12/2023 FY | -0.60 | - | - |
| Next Report Date | 11th Aug 2022 |
| Estimated EPS Next Report | -0.06 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 43.01K |
| Shares Outstanding | 17.70K |
| Shares Float | 16.26M |
| Trades Count | 219 |
| Dollar Volume | 54.93K |
| Avg. Volume | 58.23K |
| Avg. Weekly Volume | 44.30K |
| Avg. Monthly Volume | 68.08K |
| Avg. Quarterly Volume | 62.32K |
Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) stock closed at 1.25 per share at the end of the most recent trading day (a -8.09% change compared to the prior day closing price) with a volume of 56.55K shares and market capitalization of 21.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Aridis Pharmaceuticals Inc. CEO is Vu Truong.
The one-year performance of Aridis Pharmaceuticals Inc. stock is -82.76%, while year-to-date (YTD) performance is -46.35%. ARDS stock has a five-year performance of %. Its 52-week range is between 0.88 and 7.72, which gives ARDS stock a 52-week price range ratio of 5.12%
Aridis Pharmaceuticals Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 15.71, a price-to-sale (PS) ratio of 13.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -223.31%, a ROC of -770.63% and a ROE of 319.08%. The company’s profit margin is -%, its EBITDA margin is -3 503.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aridis Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Aridis Pharmaceuticals Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for Aridis Pharmaceuticals Inc. is Strong Buy (1), with a target price of $9.67, which is +686.18% compared to the current price. The earnings rating for Aridis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aridis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aridis Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.02, ATR14 : 0.14, CCI20 : 19.85, Chaikin Money Flow : 0.16, MACD : 0.06, Money Flow Index : 70.31, ROC : 17.92, RSI : 49.05, STOCH (14,3) : 31.51, STOCH RSI : 0.00, UO : 37.93, Williams %R : -68.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aridis Pharmaceuticals Inc. in the last 12-months were: Eric Patzer (Buy at a value of $25 047), Hasan Jafri (Buy at a value of $21 147), John F. Hamilton (Buy at a value of $9 740), Vu Truong (Buy at a value of $25 550)
Aridis Pharmaceuticals Inc.
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
CEO: Vu Truong
Telephone: +1 408 385-1742
Address: 5941 Optical Court, San Jose 95138, CA, US
Number of employees: 32
TipRanks News for ARDS
Thu, 17 Feb 2022 15:56 GMT Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from H.C. Wainwright
- TipRanks. All rights reserved.
